Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Authors:
- George LauGLGeorge Lau
- Ghassan K. Abou-AlfaGAGhassan K. Abou-Alfa
- Wattana SukeepaisarnjaroenWSWattana Sukeepaisarnjaroen
- Yoon Koo KangYKYoon Koo Kang
- Satheesh Chiradoni ThungappaSTSatheesh Chiradoni Thungappa
- Masatoshi KudoMasatoshi Kudo
- Robin Kate KelleyRKRobin Kate Kelley
- Junji FuruseJunji Furuse
- Joong-Won ParkJPJoong-Won Park
Open Access
- 31 July 2024
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (2) , 258-267
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapyNature Reviews Clinical Oncology, 2023
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2022
- Hepatocellular carcinomaNature Reviews Disease Primers, 2021
- The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of JapanJournal of Gastroenterology, 2020
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialThe Lancet Oncology, 2018
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatology International, 2017
- Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and managementJournal of Hepatology, 2014
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trialEuropean Journal of Cancer, 2012
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009